Health ❯ Healthcare ❯ Pharmaceuticals ❯ Clinical Trials

Weight Loss Drugs

Novo Nordisk Forecasts Up to 13% 2026 Sales and Profit Decline as U.S. Price Cuts Bite

Lower U.S. prices, intensifying competition, patent expiries prompted the downgrade.

Lilly Reports Zepbound Plus Taltz Beat Taltz Alone in Psoriatic Arthritis Trial

Lilly’s Triple‑Agonist Retatrutide Delivers Up to 28.7% Weight Loss in Phase 3, Easing Knee Pain

Wave Life Sciences Soars on Obesity Trial Signal as It Begins $250 Million Stock Offering